ANALYSTS: OUTLOOK GETTING CLOUDIER FOR BOSTON SCIENTIFIC'S STENT PRODUCTS
Boston Scientific is facing serious challenges to its product lines, analysts say.
Those challenges include a lack of visibility in the implantable cardioverter-defibrillator market, mounting competition in the European drug-eluting stent market, the timing of U.S. approval for the Taxus Liberté stent and a lack of visibility on the internal new product pipeline, RBC Capital Markets analyst Phil Nalbone said in a Jan. 11 research note.
In looking at the firm's projected fourth-quarter 2006 earnings, sales of its core products declined 1 percent, to roughly $1.52 billion, and the firm's Guidant products overall were down 2.5 percent from the year-earlier $556 billion, Nalbone said.
Overseas, preliminary sales of the firm's Taxus drug-eluting stent came in "about $13 million below our forecast of $177 million, which underscores the competitive pressures Boston Scientific is facing in the drug-eluting stent market," Nalbone said.
Upcoming Events
-
18Jul
-
21Oct